vTv Therapeutics Inc.
NASDAQ:VTVTBiotechnology
+$0.50 today
- Market cap
- $64.17M
- Beta
- 0.27
- P/E (TTM)
- 128.7
- EPS (TTM)
- $0.27
Volume 0.02M
Average 0.05M
VTVT EBITDA
Earnings before interest, taxes, depreciation, and amortization; a proxy for operating profit before non-cash and financing charges.
vTv Therapeutics Inc.NASDAQ: VTVT
EBITDA · Q1 FY2026 · quarter ended Mar 2026
EBITDA turns positive
Q1 FY2026 EBITDA was $24.14M, compared with -$6.21M a year earlier. Trailing-twelve-month EBITDA was -$715K.
Context
- EBITDA grew in size in 2 of the last 3 fiscal years.
- FY2025 was the largest annual figure in the 4 fiscal years shown.
What to watch
Whether EBITDA reaches the consensus estimate from 4 analysts of -$14.4M (+53.6%) for the fiscal year ending Dec 2026, a step up from the -37.9% reported in FY2025.
Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterMar 2026
- $24.14M+438.3% QoQ
- Last fiscal yearDec 2025
- -$31.06M-37.9% YoY
- LTMMar 2026
- -$715K+96.9% YoY
| Horizon | Past | Forecast | Difference |
|---|---|---|---|
| Quarter | +488.8% | -63.3% | -552.1 pp |
| 1 year | -37.9% | +53.6% | +91.6 pp |
| 3-year CAGR | — | — | — |
| 5-year CAGR | — | — | |
| 10-year CAGR | — | — |
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
EBITDA history
USD · from the income statement
- Latest · FY2025
- (31.06M) USD
- Year-over-year change
- -37.9%
| Period | Period end | EBITDA | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (31.06M) | -37.9% |
| FY2024 | 2024-12-31 | (22.52M) | +12.9% |
| FY2023 | 2023-12-31 | (25.86M) | -4.4% |
| FY2022 | 2022-12-31 | (24.77M) | -41.4% |
| FY2021 | 2021-12-31 | (17.52M) | — |
EBITDA vs competitors
How VTVT compares with its peers on the latest reported figures
- VTVT's LTM Mar 2026 EBITDA of -$715K is the 2nd highest of the 9 companies compared; the peer median is -$22.67M.
- Its year-over-year change of +96.9% is the 2nd highest of 9, against a peer median of -0.1%.
- EBITDA amounts to 1.9% of revenue for VTVT, versus a peer median of 620.6%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $148.02M | +264.5% | — | 223.7% | |
| LTM Mar 2026 | -$715K | +96.9% | — | 1.9% | |
| LTM Mar 2026 | -$12.3M | -29.1% | — | — | |
| LTM Mar 2026 | -$20.2M | +0.1% | — | — | |
| LTM Jun 2026 | -$22.02M | +66.8% | — | 104.8% | |
| LTM Mar 2026 | -$23.33M | -0.3% | — | 1017.5% | |
OSTXOS Therapies Incorporated | LTM Mar 2026 | -$34.71M | -256.5% | — | — |
| LTM Mar 2026 | -$36.2M | +34.4% | — | — | |
| LTM Mar 2026 | -$62.08M | -482.8% | — | 18634.1% | |
| Peer median (excluding VTVT) | -$22.67M | -0.1% | — | 620.6% | |
Competitors are the stored peer set for VTVT. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 4.01M | 2.02M | 0 | 1.02M | 0 |
| Cost of Revenue | 0 | 0 | 0 | 0 | 0 |
| Gross Profit | 4.01M | 2.02M | 0 | 1.02M | 0 |
| Gross Margin | 100.0% | 100.0% | — | 100.0% | — |
| Research & Development | 13.32M | 12.36M | 13.6M | 11.55M | 17.86M |
| Selling, General & Admin | 12.34M | 12.2M | 11.91M | 13.65M | 14.95M |
| Operating Expenses | 25.67M | 24.56M | 25.5M | 25.2M | 32.81M |
| Depreciation & Amortization | 89K | 92K | 90K | 89K | 16K |
| EBITDA | (17.52M) | (24.77M) | (25.86M) | (22.52M) | (31.06M) |
| EBITDA Margin | -437.3% | -1227.3% | — | -2214.0% | — |
| Operating Income | (21.66M) | (22.54M) | (25.5M) | (24.18M) | (32.81M) |
| Operating Margin | -540.9% | -1116.9% | — | -2377.6% | — |
| Interest Income | 1K | 352K | 472K | 1.57M | 1.87M |
| Interest Expense | 12K | 15K | 13K | 0 | 6K |
| Other Income / Expenses | 4.05M | (2.33M) | (464K) | 1.58M | 1.73M |
| Income Before Tax | (17.62M) | (24.87M) | (25.97M) | (22.61M) | (31.08M) |
| Pre-Tax Margin | -439.9% | -1232.6% | — | -2222.7% | — |
| Income Tax Expense | 115K | 200K | 0 | 100K | 0 |
| Net Income | (12.99M) | (19.16M) | (20.25M) | (18.46M) | (26.97M) |
| Net Margin | -324.3% | -949.7% | — | -1815.3% | — |
| EPS (Basic) | (8.29) | (9.98) | (9.71) | (3.20) | (3.20) |
| EPS (Diluted) | (8.29) | (9.98) | (9.71) | (3.20) | (3.20) |
| Weighted Avg Shares | 1.57M | 1.92M | 2.08M | 5.77M | 8.42M |
| Weighted Avg Shares (Diluted) | 1.57M | 1.92M | 2.08M | 5.77M | 8.42M |
vTv Therapeutics Inc.
NASDAQ:VTVT
Intrinsic Alpha fair value
Locked
Current Price
$16.23
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.